Skip to Content

Arnuity Ellipta Approval History

FDA Approved: Yes (First approved August 20, 2014)
Brand name: Arnuity Ellipta
Generic name: fluticasone furoate
Dosage form: Inhalation Powder
Company: GlaxoSmithKline
Treatment for: Asthma, Asthma, Maintenance

Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid for the maintenance treatment of asthma.

Development History and FDA Approval Process for Arnuity Ellipta

DateArticle
May 24, 2018Approval GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
Aug 21, 2014Approval FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide